Psilocybin for Methamphetamine Addiction

A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine

The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.

Study Overview

• Status: Recruiting
• Conditions: Methamphetamine Use Disorder
• Intervention / Treatment: Drug: Psilocybin 25 mg

Detailed Description

This is an open-label pilot study evaluating the feasibility and tolerability of a single 25 mg psilocybin dose in promoting abstinence from methamphetamine. Participants will attend 10 to 12 study visits over a period of up to six months.

Participants will be recruited from a population receiving treatment for methamphetamine dependence at a local residential treatment facility. Recruitment will involve informative presentations to current clients and counselor-facilitated referrals based on provided inclusion criteria. Prescreening will utilize information collected by the treatment center during the client's admission process.

Individuals who meet prescreening criteria will be invited to an in-person screening visit, conducted after obtaining informed consent. The screening visit will include a clinical review, a detailed psychiatric interview, self-report questionnaires, a comprehensive medical history, and safety laboratory testing, including blood draws.

Once eligibility is confirmed, participants will proceed with study enrollment and complete baseline assessments, which will measure substance use, quality of life, and executive function. Three preparatory sessions will follow over a two-week period to establish trust and rapport between participants and session monitors, educate participants on the study protocol, and prepare them for the psilocybin session. Two preparatory sessions may be conducted via telehealth to enhance feasibility, while the third will be conducted in person with both the primary and secondary monitors present. A medical examination will be performed within the week preceding psilocybin administration.

Within a week of the third preparatory session, participants will attend a psilocybin administration session. Participants will arrive at the study location by 9:30 AM and undergo safety screenings, including breathalyzer testing, before psilocybin administration at approximately 10:00 AM. Participants will have been instructed to consume a low-fat breakfast prior to arrival. During the session, cardiovascular measures (e.g., heart rate, blood pressure) will be monitored upon arrival, hourly throughout the session, and as clinically indicated.

The psilocybin session, lasting approximately 6-8 hours, will be monitored by both the primary and secondary session monitors, ensuring that at least one individual is present with the participant at all times. At the conclusion of the session, participants will complete questionnaires assessing their subjective experiences. Participants will then be released into the care of treatment center staff, who will provide emotional support. Participants will also receive contact information for the primary monitor to access support if needed.

Post-session integration will include two telehealth sessions: the first within one day of the psilocybin session and the second approximately 7 days later (±3 days). These sessions will provide opportunities to discuss insights or challenges arising from the psilocybin experience, with an emphasis on promoting adaptive cognitive and behavioral changes.

Follow-up assessments will occur via telehealth at 30 and 60 days post-psilocybin, with an in-person assessment conducted at 120 days. The final visit will include a urine drug screen.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Kevin S Murnane, PhD; Phone Number: (318) 675-7830; Email: kevin.murnane@lsuhs.edu
• Study Contact Backup: Name: John A Vanchiere, MD, PhD; Phone Number: (318)675-7103; Email: john.vanchiere@lsuhs.edu

Study Locations

• United States
  • Louisiana
    • Shreveport, Louisiana, United States, 71103
      • Recruiting
      • LSU Health Shreveport

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 25-65 at time of signing informed consent
• Identification of methamphetamine as drug of choice
• Score of at least 3 on the Severity of Dependence Scale
• Have been at the designated local treatment facility for at least 7 days
• Use of methamphetamine in the month preceding admission to the treatment center
• Desire to cease methamphetamine use as indicated by a goal of complete methamphetamine abstinence on the Thoughts about Abstinence questionnaire
• All English speakers, as all neuropsychological tasks will be given in English
• No prior psychedelic use or it will have been at least 3 years since their last use of a psychedelic
• Ability to attend two telehealth and one in person preparatory session appointments to establish comfort, trust and rapport between subjects and the research team and discuss the subjects' goals and aspirations with regard to the psilocybin administration.
• Ability to attend two integration sessions via telehealth and 3 follow-up assessments in person and via telehealth.
• Diagnosis of Stimulant Use Disorder - Amphetamine type on the MINI (Mini International Neuropsychiatric Interview), with no other substance dependence diagnoses other than nicotine or cannabis
• In acute remission from methamphetamine for at least 7 days prior to experimental drug administration as assessed by self-report and confirmed by urine drug screen (UDS) as well as the lack of any acute signs of intoxication on psychoactive drugs other than nicotine

Exclusion Criteria:

• Meeting criteria for substance dependence diagnoses other than methamphetamine (except nicotine and cannabis) as assessed by the MINI
• History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder
• Women who are pregnant, plan to become pregnant, or are breast feeding
• Women who do not agree to engage in abstinence or are not using dual contraceptive methods at the time of enrollment and for the study duration
• Current hypertension (exceeding 140 systolic and 90 diastolic at resting as described below) at screening or during vitals taken pre-dosing
• Heart rate of less than 60 bpm and greater than 100 bpm at screening or during vitals taken pre-dosing
• QTc of less than 350 msec or more than 460 msec
• History of cardiovascular disease (other than controlled hypertension) or cerebral vascular disease
• Unstable medical or psychiatric conditions or disorders as determined at the discretion of the attending psychiatrist
• Clear diagnosis of schizophrenia or type 1 bipolar disorder (clear from confusion with drug-induced acute states)
• Having current or recent (last 6 months) suicidal ideation, assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
• Subjects currently taking medications on the prohibited medications list or that are unwilling/unable to cease medication
• History of significant brain injury or seizure disorder
• Inability to understand the informed consent, study purpose and procedures, or other study materials involved in the research study
• Those with moderate to severe hepatic impairment, as assessed by laboratory parameters.
• Plans to move away from Shreveport-Bossier area in the next 6 months

• Subjects whose laboratory blood tests demonstrate clinically significant abnormalities. Clinically acceptable ranges listed below:

  • Complete Blood Count (CBC) Red Blood Cell Count (RBC): 4.5 - 6.0 million cells/µL

Hemoglobin (Hb or Hgb):

• For men: 13.8 - 17.2 g/dL
• For women: 12.1 - 15.1 g/dL

Hematocrit (Hct):

• For men: 38.3% - 48.6%

• For women: 35.5% - 44.9% White Blood Cell Count (WBC): 4,500 - 11,000 cells/µL Platelet Count: 150,000 - 450,000 cells/µL

  • Blood Chemistry with Liver Function Tests Alanine Transaminase (ALT): 7 - 56 units/L Aspartate Transaminase (AST): 8 - 48 units/L Bilirubin (Total): 0.2 - 1.2 mg/dL
  • Renal Function Tests Blood Urea Nitrogen (BUN): 7 - 20 mg/dL Creatinine: 0.6 - 1.3 mg/dL
  • If there are abnormalities, or if the results are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to not be clinically significant, or indicative of an unstable medical condition.

Prohibited Medications If subjects have a history of taking the following medications, they should be discontinued at least 5 half-lives prior to administering psilocybin.

• Medications that antagonize the serotonin 2A receptor
• Medications with serotonergic activity (e.g., SSRIs, SNRIs, efavirenz, lithium)
• Medications that inhibit UGT1A9 or UGT1A10 enzymes
• Monoamine Oxidase Inhibitors (MAOIs)
• Medications that inhibit aldehyde or alcohol dehydrogenase

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Psilocybin; Participants will be administered 25mg of Psilocybin.	Drug: Psilocybin 25 mg; 25 mg administered orally (capsules)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Screening, Visit #1
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Baseline Assessments, Visit #2
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing)
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing)
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	Day of drug administration, Visit #6 (on study day 0)
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	1-Day post drug administration integration session, Visit #7
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	7-Day post drug administration integration session, Visit #8
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	30-days post drug administration follow-up (Follow-up #1), Visit #9
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	60-days post drug administration follow-up (Follow-up #2), Visit #10
Participant retention rate	Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: Retention rate (percent of scheduled study visits completed by each participant).	120-days post drug administration follow-up (Follow-up #3), Visit #11 (Final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Urine drug screen results (positive/negative for methamphetamine).	Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Urine drug screen results (positive/negative for methamphetamine).	Day of drug administration, Visit #6 (on study day 0)
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Urine drug screen results (positive/negative for methamphetamine).	120 days post drug administration (Follow up #3), Visit #11(final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.	Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.	30 day post drug administration (Follow up #1), Visit #9
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.	60 day post drug administration (Follow up #2), visit #10
Preliminary efficacy of psilocybin on methamphetamine abstinence	Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days.	120 days post drug administration (Follow up #3), visit #11
Mystical experiences associated with psilocybin administration	Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: Mystical Experience Questionnaire (MEQ-30): Total score range = 0-150; higher scores indicate a more intense mystical experience.	Day of drug administration, Visit #6 (on study day 0)
Challenging experiences associated with psilocybin administration	Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: Challenging Experience Questionnaire (CEQ): Total score range = 0-200; higher scores indicate a more challenging experience.	Day of drug administration, Visit #6 (on study day 0)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Heart rate (beats per minute).	Baseline - Visit #2
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Heart rate (beats per minute).	Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Heart rate (beats per minute).	Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Heart rate (beats per minute).	Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Blood pressure (systolic/diastolic, mmHg).	Baseline - Visit #2
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Blood pressure (systolic/diastolic, mmHg).	Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Blood pressure (systolic/diastolic, mmHg).	Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration	Description: The physiological effects of psilocybin will be monitored using cardiovascular measures collected before, during, and after drug administration. Measure: Blood pressure (systolic/diastolic, mmHg).	Post-session monitoring day of drug administration - Visit #6 (on study day 0)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effects of psilocybin on quality of life	Description: Quality of life will be assessed using a validated self-report questionnaire. Measure: Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.	Baseline assessment, visit #2
Effects of psilocybin on quality of life	Description: Quality of life will be assessed using a validated self-report questionnaire. Measure: Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.	30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on quality of life	Description: Quality of life will be assessed using a validated self-report questionnaire. Measure: Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.	60 day post drug administration (Follow up #2), Visit #10
Effects of psilocybin on quality of life	Description: Quality of life will be assessed using a validated self-report questionnaire. Measure: Quality of Life Questionnaire (QOL): Score range = 14-70; higher scores indicate greater life satisfaction.	120 days post drug administration (Follow up #3), Visit #11
Effects of psilocybin on negative affect	Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale. Measure: Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.	Baseline assessment, Visit #2
Effects of psilocybin on negative affect	Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale. Measure: Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.	30 day post drug administration (Follow up #1), Visit #9
Effects of psilocybin on negative affect	Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale. Measure: Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.	60 day post drug administration (Follow up #2), visit #10
Effects of psilocybin on negative affect	Description: Symptoms of depression, anxiety, and stress will be assessed using a validated self-report scale. Measure: Depression Anxiety and Stress Scale (DASS-21): Score range = 0-126; higher scores indicate more severe negative affect.	120 days post drug administration (Follow up #3), Visit #11

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effects of psilocybin on cognitive flexibility	Description: Cognitive flexibility will be assessed using a neuropsychological test that measures executive function and task-switching ability. Measure: Trail Making Test (TMT Part B): Time to completion (seconds); shorter time indicates better executive function.	Baseline, visit #2
Effects of psilocybin on cognitive processing speed	Description: Cognitive processing speed will be assessed using a standardized neuropsychological task. Measure: Digit Symbol Substitution Task (DSST): Number of correct responses in 90 seconds; higher scores indicate better cognitive processing speed.	120 days post-drug administration (Follow Up #3), Visit #11.
Effects of psilocybin on inhibitory control	Description: Inhibitory control will be assessed using a validated cognitive task that measures response inhibition. Measure: Stroop Color and Word Task: Reaction time (milliseconds); shorter reaction times indicate better inhibitory control.	Baseline, visit #2
Effects of psilocybin on inhibitory control	Description: Inhibitory control will be assessed using a validated cognitive task that measures response inhibition. Measure: Stroop Color and Word Task: Reaction time (milliseconds); shorter reaction times indicate better inhibitory control.	120 days post-drug administration (Follow Up #3), Visit #11

Collaborators and Investigators

• Sponsor: Kevin Murnane
• Investigators: Principal Investigator: Kevin S Murnane, PhD, Louisiana State University Health Science Center Shreveport

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027

Study Registration Dates

• First Submitted: November 27, 2024
• First Submitted That Met QC Criteria: March 25, 2025
• First Posted (Actual): March 28, 2025

Study Record Updates

• Last Update Posted (Estimated): October 7, 2025
• Last Update Submitted That Met QC Criteria: October 2, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Addiction; Abstinence; Substance Use Disorder; Psilocybin; Psychedelics; Methamphetamine; Methamphetamine Use Disorder; Methamphetamine Addiction; Stimulant Use Disorder
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Compulsive Behavior; Impulsive Behavior; Behavior; Substance-Related Disorders; Behavior, Addictive; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Alkaloids; Indoles; Indole Alkaloids; Indolizidines; Indolizines; Tryptamines; Psilocybin
• Other Study ID Numbers: STUDY00002094

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No